Breast cancer treatments: updates and new challenges
A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov… - The lancet …, 2018 - thelancet.com
Background Although several randomised trials in patients with triple-negative breast cancer
have shown that the addition of carboplatin, with or without poly (ADP-ribose) polymerase …
have shown that the addition of carboplatin, with or without poly (ADP-ribose) polymerase …
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
V Diéras, HS Han, B Kaufman, H Wildiers… - The lancet …, 2020 - thelancet.com
Background BRCA1 or BRCA2-mutated breast cancers are sensitive to poly (ADP-ribose)
polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous …
polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous …
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast
cancer (TNBC) in which the three major receptors ie estrogen receptor (ER), progesterone …
cancer (TNBC) in which the three major receptors ie estrogen receptor (ER), progesterone …
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a …
PM Morice, A Leary, C Dolladille, B Chrétien… - The Lancet …, 2021 - thelancet.com
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …
Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline
NM Tung, JC Boughey, LJ Pierce… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE To develop recommendations for management of patients with breast cancer
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …
Recent advances in the treatment of breast cancer
Breast cancer (BC) is the most common malignancy in women. It is classified into a few
major molecular subtypes according to hormone and growth factor receptor expression …
major molecular subtypes according to hormone and growth factor receptor expression …
[HTML][HTML] Genetic markers in triple-negative breast cancer
Z Sporikova, V Koudelakova, R Trojanec… - Clinical breast cancer, 2018 - Elsevier
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …
is characterized by the absence of estrogen, progesterone, and human epidermal growth …